{"id":18566,"date":"2025-09-08T11:54:18","date_gmt":"2025-09-08T11:54:18","guid":{"rendered":"https:\/\/blogemergencias.es\/index.php\/2025\/09\/08\/un-ensayo-espanol-de-quimio-inmunoterapia-logra-reducir-las-recaidas-en-cancer-de-pulmon\/"},"modified":"2025-09-08T11:54:18","modified_gmt":"2025-09-08T11:54:18","slug":"un-ensayo-espanol-de-quimio-inmunoterapia-logra-reducir-las-recaidas-en-cancer-de-pulmon","status":"publish","type":"post","link":"https:\/\/blogemergencias.es\/index.php\/2025\/09\/08\/un-ensayo-espanol-de-quimio-inmunoterapia-logra-reducir-las-recaidas-en-cancer-de-pulmon\/","title":{"rendered":"Un ensayo espa\u00f1ol de quimio-inmunoterapia logra reducir las reca\u00eddas en c\u00e1ncer de pulm\u00f3n"},"content":{"rendered":"<div data-aida-text=\"\"><!----><!----><!----><!--[--><!--[--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">La combinaci\u00f3n de <strong>quimioterapia e inmunoterapia tras la cirug\u00eda <\/strong>en pacientes de<strong> <\/strong><a class=\"ft-link ft-link--decoration broken_link\" href=\"https:\/\/www.elperiodico.com\/es\/temas\/cancer-8893\" target=\"_blank\"><strong>c\u00e1ncer de pulm\u00f3n<\/strong><\/a> en fase inicial reduce significativamente el<strong> riesgo de reca\u00edda, <\/strong>seg\u00fan las conclusiones preliminares de un <strong>ensayo del Grupo Espa\u00f1ol de C\u00e1ncer de Pulm\u00f3n (GECP)<\/strong> presentado en el Congreso Mundial de C\u00e1ncer de Pulm\u00f3n (WCLC 2025).<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El estudio quiso aplicar el <strong>esquema que la medicina espa\u00f1ola<\/strong> ya convirti\u00f3 hace a\u00f1os en est\u00e1ndar en todo el mundo para tratar a pacientes con ambas terapias cuando estaban <strong>en fase avanzada <\/strong>y no pod\u00edan ser operados o comportaba riesgos, ha explicado el presidente del GECP, el doctor Mariano Provencio.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext ft-helper-hide-md\"\/><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext  ft-helper-hide-xs\"\/><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El tambi\u00e9n jefe de Oncolog\u00eda M\u00e9dica del Hospital Universitario Puerta de Hierro ha explicado que decidieron estudiar si tambi\u00e9n ten\u00eda buen resultado esa<strong> combinaci\u00f3n en estadios iniciales de tumores en el pulm\u00f3n con riesgo de reca\u00edda tras la cirug\u00eda.<\/strong><\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">A los tres a\u00f1os de seguimiento de los pacientes con este tratamiento combinado<strong>, solo un 20,4% hab\u00eda reca\u00eddo,<\/strong> frente al 38,8% de los que recibieron \u00fanicamente inmunoterapia.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El estudio, en el que han participado<strong> 206 pacientes de 30 hospitales en Espa\u00f1a,<\/strong> se ha presentado en el Presidential Symposium, el <strong>foro cient\u00edfico de mayor prestigio del congreso mundial, <\/strong>dedicado al c\u00e1ncer con m\u00e1s mortalidad.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Se trata del <strong>primer ensayo fase III<\/strong> en el mundo que eval\u00faa la inmunoterapia en el contexto adyuvante (tras cirug\u00eda) en el <strong>c\u00e1ncer de pulm\u00f3n no microc\u00edtico.<\/strong><\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext ft-helper-hide-md\"\/><!--]--><!--[--><\/p>\n<aside class=\"ft-ad ft-ad--intext  ft-helper-hide-xs\"\/><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El GECP tambi\u00e9n ha presentado otros an\u00e1lisis derivados del <strong>ensayo &#8216;NADIM II&#8217;, <\/strong>as\u00ed como los resultados obtenidos a partir de su<strong> Registro de Tumores Tor\u00e1cicos, <\/strong>una de las bases de datos m\u00e1s amplias de Europa en c\u00e1ncer de pulm\u00f3n, con cerca de <strong>40.000 pacientes incluidos.<\/strong><\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Igualmente, el doctor<strong> Bartomeu Massuti, <\/strong>jefe de Oncolog\u00eda del Hospital doctor Balmis de Alicante, ha presentado un an\u00e1lisis farmacoecon\u00f3mico sobre el <strong>coste-efectividad de la quimio-inmunoterapia <\/strong>perioperatoria en tumores de pulm\u00f3n en estadios iniciales.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><\/p>\n<aside class=\"ft-ad ft-ad--roba ft-ad--robaNotext ft-helper-hide-md\"\/><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">Tambi\u00e9n, el doctor <strong>Enric Carcereny <\/strong>(Hospital Germans Trias i Pujol, Badalona) presentar\u00e1 un an\u00e1lisis sobre el<strong> impacto de la inmunoterapia en la supervivencia<\/strong> de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El Congreso Mundial de C\u00e1ncer de Pulm\u00f3n (WCLC 2025) re\u00fane en Barcelona desde el s\u00e1bado pasado y <strong>hasta el 9 de septiembre a m\u00e1s de 7.000 especialistas <\/strong>en oncolog\u00eda tor\u00e1cica de todo el mundo.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!--[--><!----><!----><!--]--><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--[--><!----><!----><!--[--><\/p>\n<p class=\"ft-text\">El presidente de la organizadora IASLC, Alex A. Adjei, ha destacado a los medios la<strong> lacra mundial del c\u00e1ncer de pulm\u00f3n<\/strong> y la contribuci\u00f3n cada vez mayor de tratamientos multidisciplinares, tal y como dan cuenta buena parte de los ensayos cl\u00ednicos presentados.<\/p>\n<p><!--]--><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!----><!--[--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--[--><!----><!--]--><!--]--><!----><!----><!--]--><!--]--><!--[--><!----><!--[--><!--]--><!----><!--[--><!----><!----><!----><!--]--><span\/><!--]--><!--]--><!----><\/div>\n<p><a href=\"https:\/\/www.elperiodico.com\/es\/sanidad\/20250908\/ensayo-espanol-quimio-inmunoterapia-logra-reducir-recaidas-cancer-pulmon-121354148?utm_source=rss-noticias&amp;utm_medium=feed&amp;utm_campaign=sanidad\" class=\"broken_link\">source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La combinaci\u00f3n de quimioterapia e inmunoterapia tras la cirug\u00eda en pacientes de c\u00e1ncer de pulm\u00f3n en fase inicial<\/p>\n","protected":false},"author":1,"featured_media":39752,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_joinchat":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"featured_image_urls":{"full":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=1920&resize=1920,998&ssl=1",1920,998,false],"thumbnail":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=150&resize=150,150&ssl=1",150,150,false],"medium":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=300&resize=300,300&ssl=1",300,300,false],"medium_large":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=768&resize=768,0&ssl=1",768,0,false],"large":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=1024&resize=1024,1024&ssl=1",1024,1024,false],"1536x1536":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=1536&resize=1536,1536&ssl=1",1536,1536,false],"2048x2048":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=2048&resize=2048,2048&ssl=1",2048,2048,false],"morenews-large":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=825&resize=825,575&ssl=1",825,575,false],"morenews-medium":["https:\/\/i3.wp.com\/blogemergencias.es\/wp-content\/uploads\/2025\/02\/IMAGEN-ESTANDAR-BLOGEMERGENCIAS-ENTRADAS.png?w=590&resize=590,410&ssl=1",590,410,false]},"author_info":{"info":["admin"]},"category_info":"<a href=\"https:\/\/blogemergencias.es\/index.php\/category\/noticias\/\" rel=\"category tag\">Noticias<\/a>","tag_info":"Noticias","comment_count":0,"_links":{"self":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts\/18566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/comments?post=18566"}],"version-history":[{"count":0,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/posts\/18566\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/media\/39752"}],"wp:attachment":[{"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/media?parent=18566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/categories?post=18566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogemergencias.es\/index.php\/wp-json\/wp\/v2\/tags?post=18566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}